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Automated, Solid-Phase Synthesis of C-Neoglycopeptides: Coupling of
Glycosyl Derivatives to Resin-Bound Peptides1
Kristina M. K. Kutterer, Michael L. Barnes, and Prabhat Arya*
Steacie Institute for Molecular Sciences, National Research Council of Canada,
Ottawa, Ontario, Canada K1A 0R6
ReceiVed June 30, 1998
A fully automated solid-phase synthesis of C-neoglycopeptides has been developed using a convergent
strategy. In this approach, C-glycoside derivatives (3 and 4) were coupled to resin-bound peptides using a
peptide synthesizer. An advantage of the convergent approach is the ability to introduce multiple glycoside
units late in the synthesis. The approach presented is highly versatile and efficient and could be used for
building C-neoglycopeptide libraries. In our study, neoglycopeptides 5 and 6 were obtained from the coupling
of C-glycoside derivatives (3 and 4) to a free amino group of the side chain of short peptides (2, n ) 1 and
3). A similar approach was developed for the synthesis of bivalent neoglycopeptides 8 and 9 in an automated
manner. The successful syntheses of C-neoglycopeptides 5, 6, 8, and 9 are the first examples of coupling
of C-glycosyl carboxyl derivatives to the amino groups of the side chains of resin-bound peptides.
As a post-translational process, glycosylation of proteins
is responsible for the incorporation of highly branched
carbohydrate units onto the side chain of several amino acids
of the peptide backbone. The two most common sites involve
asparagine and serine/threonine amino acid moieties, result-
ing in N- and O-linked glycoproteins. Glycoconjugates (i.e.,
glycolipids and glycoproteins) play a key role in initiating a
diverse range of biological and pathological processes such
as cell-cell recognition, fertilization, bacterial/viral infec-
tions, inflammation, and tumor metastasis.2 Unlike protein-
protein and nucleotide-protein interactions, carbohydrate-
based interactions are weak and are difficult to study. In
natural systems, in order to compensate for the weak forces
which characterize carbohydrate-protein interactions, it is
well recognized that nature employs cooperativity to over-
come individual weak ligand-receptor interactions.3 Model
compounds that are based upon carbohydrate conjugate
derivatives would be valuable tools in contributing to the
understanding of some of these biological and pathological
processes. As a long-term goal, mimics of carbohydrate
conjugates that are capable of preventing these interactions
offer various applications, ranging from antimicrobial agents4
to antifertility agents.5
Over the years, various groups have developed elegant
strategies for the synthesis of segments of glycoproteins (i.e.,
glycopeptides) as glycoconjugate derivatives.6 Despite several
efforts, the synthesis of glycopeptides still remains a chal-
lenging area. An important strategy for the synthesis of
glycopeptides consists of a solid-phase approach involving
glycosylated building blocks. As an alternative to the
assembly of building blocks, a convergent solid-phase
approach for the synthesis of glycopeptides could prove to
be more expedient.7 The first attempt toward this strategy
for the synthesis of N-linked glycopeptides was reported by
the Affymax group.7a A key step in their approach involved
the coupling of an unprotected galactosylamine to a pen-
tafluorophenyl carboxyl ester moiety of the resin-bound
peptide moiety.
Recently, there has been much emphasis on the synthesis
of small molecules as analogues of cell-surface carbohydrate
ligands and as probes for obtaining molecular level under-
standing of carbohydrate-protein interactions.8 We are
developing a flexible and control-oriented model for the
synthesis of carbon-linked neoglycopeptides in order to
design inhibitors of carbohydrate-protein mediated interac-
tions that involve cell-surface carbohydrates. Our approach
is based upon presenting terminal or exposed C-glycosides
on a peptide/pseudo-peptide template. This would provide
controlled, yet broad, structural variation possibilities for
displaying C-glycoside derivatives (see Figure 1).9 With
ourmodel, it is plausible that the peptide portion of the
C-linked neoglycopeptides may assist in secondary interac-
tions with adjacent amino acid residues, aiding in overcoming
the inherent weakness of carbohydrate-protein interactions.
The long-term goal is to assemble combinatorial libraries of
C-linked neoglycopeptides and screen them for developing
inhibitors of cell-surface carbohydrate mediated interac-
tions.10
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For designing inhibitors that are based upon C-linked
neoglycopeptides, initial studies in our group are focused
on using R-C-galactoside derivatives. R-Galactose is the
terminal saccharide of the globotriosylceramide (Gb3) which
is present on the cell surface of human endothelial cells. It
has been shown that the Gb3 ligand is responsible for the
binding of Escherichia coli produced verotoxin receptors.11
The binding subunits of verotoxin are lectins that recognize
the galabiose moiety (GalR1â4Gal) of glycosphingolipid
derivatives. Among several galabiose-based glycosphin-
golipid derivatives, Gb3 has shown to be one of the effective
cell-surface ligands for the binding of verotoxin toxin
receptors. The initial carbohydrate ligand-lectin receptor
recognition with verotoxin is followed by the endocytosis
of the toxic subunit leading to hemorrhagic colitis and
hemolytic uremic syndrome in humans. Novel compounds
that could interfere with Gb3 glycoconjugate ligand-vero-
toxin receptor interactions offer new therapeutic approaches
to prevent toxin adhesion. Currently, work is in progress to
explore various R-galactoside-based C-linked neoglycopep-
tides as possible inhibitors of Gb3 ligand-verotoxin receptor
interactions.12
The synthesis of a few C-linked neoglycopeptides, using
solution-phase synthesis of the building blocks followed by
building block assembly on solid phase, has been achieved
by our group.9c In contrast to the synthesis of O-glycopep-
tides, activation of the glycosylated building block prior to
the coupling was not required.6b Herein, we report a fully
automated solid-phase synthesis of C-linked neoglycopep-
tides.13 An advantage of this approach is an overall increase
in efficiency in terms of time, labor, and yields. Another
advantage is the ability to introduce multiple saccharide units
in the final step before cleavage from the resin. Due to the
reasons listed, this approach is adaptable to the future
formation of combinatorial libraries. In a convergent ap-
proach, coupling of the C-glycoside derivative to the resin-
bound peptide/pseudo-peptides has been developed using a
peptide synthesizer (Schemes 1 and 2).7 To our knowledge,
the synthesis of C-neoglycopeptides 5, 6, 8, and 9 demon-
strate the first example of the coupling of the carboxyl group
of a C-glycoside derivative to a resin-bound peptide/pseudo-
peptide.
Syntheses of neoglycopeptides (5, 6, 8, and 9) were
performed utilizing a PerSeptive Biosystems Pioneer peptide
synthesis system. Fmoc-PAL-PEG-PS resin14 (PerSeptive
BioSystems, loading 0.16 mmol/g) was treated with 20%
piperidine in DMF to remove the Fmoc group. Amino acids
were sequentially coupled with the free amino group on the
resin using the HATU coupling method (4.0 equiv amino
acid, 4.0 equiv HATU, 8.0 equiv DIEA in DMF, 1 h).
Coupling was always followed by Fmoc removal with 20%
piperidine in DMF, except for the final step in the sequence,
in which case the Fmoc protecting group was retained.
Following the preparation of the desired amino acid se-
quence, the alloc protecting group(s), on the side chain of
lysine, were removed using 4.0 equiv of Pd[P(Ph)3]4. A
chloroform solution of 5% HOAc and 2.5% N-methylmor-
pholine was used in conjunction with the Pd[0] reagent. The
deprotection step was succeeded by a washing step utilizing
a solution of 0.5% sodium diethylthiocarbamate and 0.5%
DIEA in DMF to scavenge any remaining palladium. The
final, on resin, step consisted of coupling the glycoside
monomer unit (either 3 or 4) to the peptide sequence.
C-Linked glycoside based monomer units 3 and 4 were
obtained by solution-phase synthesis.15 The final step on solid
phase was accomplished using standard HATU coupling
procedures with coupling times of 16 h. For cases where
two glycoside units were being added, two consecutive 16
h couplings were performed. This completes the automated
synthesis of the neoglycopeptides (Schemes 1 and 2).
Cleavage of the neoglycopeptides from the resin was effected
with 95% TFA. Crude neoglycopeptides were purified by
reverse-phase HPLC. Overall yields were on the order of
50-65% for the addition of one glycoside unit (compounds
5 and 6) and 15-20% for the bivalent neoglycopeptides 8
and 9.
The methodology presented here is highly versatile for
the synthesis of C-linked neoglycopeptides and for the
simultaneous coupling of multiple glycoside units. This has
been demonstrated by the coupling of two C-glycoside
derivatives (3 and 4) to different resin-bound peptides via
an automated process. Using this convergent approach, it is
possible to obtain libraries of a wide variety of C-neogly-
copeptides. Currently, work is in progress to build a library
of bivalent forms of monomeric, R-galactosyl based N-
terminal branched amino acid derivative, an inhibitor for the
binding of verotoxin to Gb3.12b
Experimental Section
Neoglycopeptide, 5. 1H NMR (400 MHz, CDCl3): δ 1.42
(br d, J ) 3.7 Hz, 2H), 1.56 (br s, 2H), 1.73-1.84 (m, 2H),
2.02 (s, 3H), 2.05 (s, 6H), 2.13 (s, 3H), 2.44-2.76 (m, 2H),
3.30 (br s, 2H), 3.94-4.06 (m, 3H), 4.18-4.22 (m, 3H),
4.28-4.33 (m, 1H), 4.37-4.46 (m, 2H), 4.70 (t, J ) 4.9
Hz, 1H), 5.18 (dd, J ) 2.8 Hz, J ) 9.0 Hz, 1H), 5.30 (dd,
J ) 4.8 Hz, J ) 8.8 Hz, 1H), 5.40 (br s, 1H), 6.04 (br s,
1H), 6.94-7.06 (m, 3H), 7.28-7.33 (m, 2H), 7.39-7.43 (m,
3H), 7.59 (d, J ) 6.9 Hz, 2H), 7.77 (d, J ) 7.4 Hz, 2H). 13C
NMR (100 MHz, CDCl3): δ 21.0, 21.1, 22.4, 28.5, 31.1,
34.2, 39.2, 42.8, 47.4, 54.8, 61.7, 67.5, 67.7, 68.0, 68.3, 69.3,
69.7, 120.5, 125.4, 127.5, 128.3, 141.7, 144.0, 157.3, 170.3,
Figure 1. Model for the presentation of glycoside derivatives on
a peptide/pseudo-peptide template.
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170.6, 170.8, 171.6, 171.8, 173.8. LRMS (electrospray, H2O,
positive ion mode, m/z) for C39H48N4O14: 797.2 (MH+).
Neoglycopeptide, 6. 1H NMR (400 MHz, CDCl3): δ 1.37
(br s, 2H), 1.47 (br s, 2H), 1.70-1.80 (m, 2H), 1.91 (br s,
2H), 1.99 (s, 3H), 2.03 (s, 6H), 2.06 (s, 3H), 2.08 (s, 6H),
2.12 (s, 3H), 2.16 (s, 3H), 2.54-2.57 (m, 1H), 3.08-3.12
(m, 1H), 3.19-3.26 (m, 2H), 3.50-3.66 (m, 2H), 3.92 (br
s, 6H), 4.04-4.35 (m, 13H), 4.86 (br s, 1H), 5.04-5.44 (m,
6H), 6.36 (br s, 1H), 7.02 (br s, 2H), 7.10 (br s, 1H), 7.30
(br s, 2H), 7.40 (t, J ) 6.8 Hz, 2H), 7.64-7.58 (m, 2H),
7.70 (br s, 1H), 7.76 (d, J ) 7.4 Hz, 2H), 7.86 (br s, 2H).
13C NMR (100 MHz, CDCl3): δ 20.9, 21.0, 21.1, 21.2, 22.6,
24.1, 28.8, 31.4, 32.4, 39.1, 42.9, 43.5, 43.8, 45.8, 47.4, 51.4,
56.0, 61.2, 62.8, 67.0, 67.3, 67.4, 67.6, 68.1, 68.2, 68.3, 68.7,
69.1, 71.0, 120.5, 125.5, 127.5, 128.2, 141.6, 144.0, 144.2,
157.4, 169.6, 170.2, 170.3, 170.4, 170.5, 170.6, 170.7, 171.1,
171.2, 171.6, 173.6. LRMS (electrospray, H2O, positive ion
mode, m/z) for C62H83N7O26: 1326.2 (MH+).
Neoglycopeptide, 8. 1H NMR (400 MHz, CD3OD): δ 1.36
(d, J ) 7.0 Hz, 3H), 1.37-1.49 (m, 4H), 1.53-1.56 (m,
4H), 1.72-1.88 (m, 4H), 2.01 (s, 3H), 2.02 (s, 9H), 2.03 (s,
3H), 2.05 (s, 3H), 2.11 (s, 3H), 2.12 (s, 3H), 2.40-2.75 (m,
4H), 3.16-3.27 (m, 4H), 3.75-4.48 (m, 18H), 4.64-4.72
(m, 2H), 5.04-5.42 (m, 6H), 7.34 (t, J ) 7.4 Hz, 2H), 7.42
(t, J ) 7.4 Hz, 2H), 7.69 (d, J ) 7.4 Hz, 2H), 7.82 (d, J )
7.4 Hz, 2H). 13C NMR (100 MHz, CD3OD): δ 16.3, 19.5,
Scheme 1. Coupling of C-Glycoside Derivatives (3 and 4) to the Resin-Bound Peptide on a Peptide Synthesizera
a Standard peptide synthesis: (a) (i) 20% piperidine/DMF, (ii) AAn (4.0 equiv), HATU (4.0 equiv), DIEA (8.0 equiv), DMF, 1 h; (b) (i) Pd[P(Ph)3]4 (4.0
equiv), 5% HOAc, 2.5% N-methylmorpholine, 2 h, (ii) 3 (4.0 equiv), HATU (4.0 equiv), DIEA (8.0 equiv), DMF, 16 h, (iii) 95% TFA; (c) same as step b(i),
(ii) 4 (4.0 equiv), HATU (4.0 equiv), DIEA (8.0 equiv), DMF, 16 h, (iii) same as step b(iii).
Scheme 2. Automated Solid-Phase Synthesis of C-Linked Neoglycopeptide Derivativesa
a Standard peptide synthesis: (a) (i) 20% piperidine/DMF, (ii) AAn (4.0 equiv), HATU (4.0 equiv), DIEA (8.0 equiv), DMF, 1 h; (b) (i) Pd[P(Ph)3]4 (8.0
equiv), 5% HOAc, 2.5% N-methylmorpholine, 2 h; (ii) 3 (8.0 equiv), HATU (8.0 equiv), DIEA (16.0 equiv), DMF, 16 h; (c) same as step b(i), (ii) 4 (8.0
equiv), HATU (8.0 equiv), DIEA (16.0 equiv), DMF, 32 h; (d) 95% TFA.
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19.6, 19.7, 19.9, 23.2, 28.8, 29.0, 30.9, 31.2, 34.0, 39.2, 42.3,
42.8, 42.9, 47.4, 50.3, 54.2, 56.0, 61.5, 67.0, 67.9, 68.0, 68.3,
69.1, 70.4, 71.5, 120.0, 125.2, 125.3, 127.2, 127.9, 141.6,
144.2, 157.8, 170.3, 170.5, 170.9, 171.2, 173.3, 173.6, 174.9.
LRMS (electrospray, H2O, positive ion mode, m/z) for
C68H91N9O28: 1482.6 (MH+), 741.9 (MH+/2).
Neoglycopeptide, 9. 1H NMR (400 MHz, CD3OD): δ 1.36
(d, J ) 6.4 Hz, 3H), 1.40-1.41 (m, 4H), 1.55-1.63 (m,
4H), 1.72-1.85 (m, 4H), 2.01-2.13 (m, 52H), 2.47-2.98
(m, 4H), 3.21 (br s, 4H), 3.37-3.76 (m, 4H), 3.88-4.45 (m,
34H), 4.72-4.98 (m, 2H), 5.08-5.43 (m, 12H), 7.34 (t, J
) 7.4 Hz, 2H), 7.42 (t, J ) 7.4 Hz, 2H), 7.69 (d, J ) 7.4
Hz, 2H), 7.83 (d, J ) 7.4 Hz, 2H). LRMS (electrospray,
H2O, positive ion mode, m/z) for C108H147N13O50: 2426.3
(MH+), 1214.6 (MH+/2), 809.9 (MH+/3).
Supporting Information Available. 1H NMR, 13C NMR,
and LRMS spectra for compounds 5, 6, 8, and 9 (23 pages).
Ordering information is given on any current masthead page.
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